AMGEN BIOSIMILARS Trademark

Trademark Overview


On Friday, March 27, 2015, a trademark application was filed for AMGEN BIOSIMILARS with the United States Patent and Trademark Office. The USPTO has given the AMGEN BIOSIMILARS trademark a serial number of 86578521. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 1, 2019. This trademark is owned by Amgen Inc.. The AMGEN BIOSIMILARS trademark is filed in the Pharmaceutical Products category with the following description:

House mark for a full line of pharmaceuticals and pharmaceutical preparations, namely, pharmaceutical preparations and substances used for the treatment of bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune, immune system, inflammatory, inflammatory bowel, gastrointestinal, genitourinary, musculoskeletal, dermatological, pulmonary, respiratory, oncological, hepatological, lymphomas, leukemias, ophthalmic, transplant rejection, cardiovascular, endocrine, neurological, sleep, muscular, and psychiatric diseases and disorders;pharmaceutical preparations and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, p...
amgen biosimilars

General Information


Serial Number86578521
Word MarkAMGEN BIOSIMILARS
Filing DateFriday, March 27, 2015
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 1, 2019
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, January 5, 2016

Trademark Statements


Disclaimer with Predetermined Text"BIOSIMILARS"
Description of MarkThe mark consists of the stylized words "AMGEN BIOSIMILARS" positioned to the right of an interweaving double ribbon design.
Goods and ServicesHouse mark for a full line of pharmaceuticals and pharmaceutical preparations, namely, pharmaceutical preparations and substances used for the treatment of bone, joint, vertebral column, intestine, colon, skin, lung, eye, breast, ovary, cervix, stomach, bladder, kidney, head, brain, neck, and blood diseases and disorders; pharmaceutical preparations and substances for the treatment of autoimmune, immune system, inflammatory, inflammatory bowel, gastrointestinal, genitourinary, musculoskeletal, dermatological, pulmonary, respiratory, oncological, hepatological, lymphomas, leukemias, ophthalmic, transplant rejection, cardiovascular, endocrine, neurological, sleep, muscular, and psychiatric diseases and disorders;pharmaceutical preparations and substances used for the treatment of arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, juvenile idiopathic arthritis, enthesitis related arthritis, osteoarthritis, peripheral spondyloarthritis, polymyalgia rheumatic, spondyloarthropathies, acute disc prolapse, inflammatory bowel disease, Crohn's disease, ulcerative colitis, Intestinal Behçet's Disease, chronic pouchitis, small bowel lesions, Hermansky-Pudlak syndrome, autoimmune pancreatitis, multiple myeloma, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, chronic inflammatory demyelinating polyneuropathy, autoimmune anemia, autoimmune hemolytic anemia, pure red cell aplasia, idiopathic thrombocytopenic purpura, Evans syndrome, type 1 diabetes mellitus, Sjogren's syndrome, encephalitis, IgG4-related disease, Devic's disease, myositis, psoriasis, psoriasis vulgaris, psoriasis arthropica, plaque psoriasis, palmoplantar psoriasis, hidradenitis suppurativa, bullous skin disorder, pemphigus, pemphigoid, kawasaki disease, interstitial cystitis, sleep apnea, sarcoidosis, retinal vascular disorders, age-related macular degeneration, refractory diabetic macular edema, uveitis, childhood uveitis, uveitic macular edema, choroidal neovascularization, Graves' ophthalmopathy, pyoderma gangrenosum, giant cell arteritis, Netherton syndrome, anaplastic thyroid cancer, breast cancer, ovarian cancer, cervical cancer, gastric cancer, colorectal cancer, non-squamous non-small cell lung cancer, glioblastoma, renal cell carcinoma, head and neck cancer, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, lymphocyte predominant subtype of Hodgkin's Lymphoma, vasculitis, granulomatosis with polyangiitis, microscopic polyangiitis, graft-versus-host disease, graft-versus-host disease following allogenic hematopoietic stem cell transplantation, graft-versus-host disease following keratoprosthesis, kidney transplant, asthma, chronic fatigue syndrome, major depression, and bipolar depression

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, April 6, 2015
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAmgen Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Party NameAmgen Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Trademark Events


Event DateEvent Description
Monday, April 1, 2019ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, April 1, 2019ABANDONMENT - NO USE STATEMENT FILED
Thursday, March 7, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, March 7, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, August 22, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 21, 2018EXTENSION 5 GRANTED
Wednesday, August 15, 2018EXTENSION 5 FILED
Tuesday, August 21, 2018CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 15, 2018TEAS EXTENSION RECEIVED
Friday, March 2, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 28, 2018EXTENSION 4 GRANTED
Wednesday, February 28, 2018EXTENSION 4 FILED
Wednesday, February 28, 2018TEAS EXTENSION RECEIVED
Thursday, August 10, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 8, 2017EXTENSION 3 GRANTED
Tuesday, August 8, 2017EXTENSION 3 FILED
Tuesday, August 8, 2017TEAS EXTENSION RECEIVED
Wednesday, March 1, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, February 27, 2017EXTENSION 2 GRANTED
Monday, February 27, 2017EXTENSION 2 FILED
Monday, February 27, 2017TEAS EXTENSION RECEIVED
Thursday, July 7, 2016NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 5, 2016EXTENSION 1 GRANTED
Tuesday, July 5, 2016EXTENSION 1 FILED
Tuesday, July 5, 2016TEAS EXTENSION RECEIVED
Tuesday, March 1, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 5, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 5, 2016PUBLISHED FOR OPPOSITION
Wednesday, December 16, 2015NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, November 12, 2015APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, November 12, 2015TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, November 11, 2015CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, November 11, 2015TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, May 18, 2015NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, May 18, 2015NON-FINAL ACTION E-MAILED
Monday, May 18, 2015NON-FINAL ACTION WRITTEN
Monday, May 11, 2015ASSIGNED TO EXAMINER
Tuesday, April 7, 2015NOTICE OF DESIGN SEARCH CODE E-MAILED
Monday, April 6, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Tuesday, March 31, 2015NEW APPLICATION ENTERED IN TRAM